Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 6935
The Licensor granted the Licensee an exclusive License to vernakalant (iv) and its related technology to develop, make and sell intravenous or injectable formulations of vernakalant (iv) in North America for any and all indications including the treatment of atrial fibrillation and atrial flutter, including a right to subLicense to third parties.
Vernakalant (INN; codenamed RSD1235, proposed tradenames Kynapid and Brinavess) is an investigational drug under regulatory review for the acute conversion of atrial fibrillation.
IPSCIO Record ID: 209524
RSD1235 is an investigational drug for the acute conversion of atrial fibrillation. RSD1235 has been demonstrated in a second phase 3 clinical trial; the acute-use intravenous antiarrhythmic agent has been shown to safely convert more patients to normal sinus rhythm than placebo.
Atrial fibrillation is an abnormal heart rhythm characterized by rapid and irregular beating of the atria.
Atrial flutter is a common abnormal heart rhythm that starts in the atrial chambers of the heart.
IPSCIO Record ID: 728
The Company will also assume all obligations to, and responsibility for, the Biovail litigation, including the costs thereof. On August 18, 2009 Licensor was sued by Biovail in the U.S. District Court of Delaware for patent infringement, under provisions of the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act), with respect to Biovail's U.S. Patent No. 6,096,341.
Product means tablets that contain 450 mg of bupropion hydrochloride extended release as described in the NDA.